FFO
LAB icon

Fortitude Family Office’s Standard BioTools LAB Stock Holding History

Fortitude Family Office’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$109 Buy
+133
New +$126 ﹤0.01% 2167
2025
Q4 		– Sell
-793
Closed -$1.03K – 2033
2025
Q3 		$1.03K Buy
+793
New +$1.04K ﹤0.01% 1535

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Fortitude Family Office's LAB Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Standard BioTools (LAB) in Q2 2026: 133 shares worth $109. The stake represents ﹤0.01% of the portfolio and ranks #2167 among its holdings. This is a return to the name: Fortitude Family Office previously reported a position in LAB as recently as Q3 2025.

Fortitude Family Office first reported a position in LAB in Q3 2025 and has held it in 2 quarters since. The position peaked at $1.03K in Q3 2025. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Fortitude Family Office held 133 shares of Standard BioTools worth $109 as of Q2 2026.
  • Standard BioTools was a new Fortitude Family Office position in Q2 2026.
  • Standard BioTools made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2167 holding.
  • Fortitude Family Office first reported a position in Standard BioTools in Q3 2025 and has held it in 2 quarters since.
  • Fortitude Family Office's Standard BioTools position peaked at $1.03K in Q3 2025.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.